Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Tabarsi, P. Baghaei, M. Marjani, M. Shamaei, D. Mansouri, M. Masjedi (Tehran, Islamic Republic Of Iran). Risk factors of drug -induced hepatitis among patients with TB/HIV co-infection. Eur Respir J 2010; 36: Suppl. 54, 3140

Member's Comments

No comment yet.

Related content which might interest you: Features the effectiveness of the treatment of moxifloxacin in patients with co-infections tuberculosis/HIV and hepatitis B,and/or C Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Features of TB/HIV co-infection and treatment outcome Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Mutual impact of HIV infection on HIV/tuberculosis co-infection Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 The risk of hepatotoxicity of anti-tuberculosis drugs in patients from regions with high prevalence of hepatitis B Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Prevalence of hepatitis c virus infection among patients with COPD Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Treatment outcomes of MDR-TB and HIV co-infection in Europe Source: Eur Respir J, 49 (6) 1602363; 10.1183/13993003.02363-2016 Year: 2017 Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity Source: International Congress 2015 – Screening strategies in TB Year: 2015 Risk factors for tuberculosis in patients with chronic alcoholism Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018 Predictors of death in patients with MDR-TB and HIV Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Timing of relapse of tuberculosis in people with co-infection (HIV/TB) Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006 High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons Source: International Congress 2015 – Screening strategies in TB Year: 2015 Predictive factors for risk of decease in tuberculosis (TB)-HIV co-infected patients Source: Annual Congress 2010 - Tuberculosis in special populations Year: 2010 Latent tuberculosis infection prevalence and risk of developing active TB among patients eligible for starting anti-TNFα therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015 Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 The twin epidemics: HIV / DR-TB co-infection in 2012 Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015 Risk factors of hepatotoxicity during tuberculosis treatment and management Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I Year: 2008